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Achieving the millennium development goals for health
Cost effectiveness analysis of strategies to combat
HIV/AIDS in developing countries
Daniel R Hogan, Rob Baltussen, Chika Hayashi, Jeremy A Lauer, Joshua A Salomon
Abstract
Objective To assess the costs and health effects of a
range of interventions for preventing the spread of
HIV and for treating people with HIV/AIDS in the
context of the millennium development goal for
combating HIV/AIDS.
Design Cost effectiveness analysis based on an
epidemiological model.
Setting Analyses undertaken for two regions classified
using the WHO epidemiological grouping—Afr-E,
countries in sub-Saharan Africa with very high adult
and high child mortality, and Sear-D, countries in
South East Asia with high adult and high child
mortality.
Data sources Biological and behavioural parameters
from clinical and observational studies and
population based surveys. Intervention effects and
resource inputs based on published reports, expert
opinion, and the WHO-CHOICE database.
Main outcome measures Costs per disability adjusted
life year (DALY) averted in 2000 international dollars
($Int).
Results In both regions interventions focused on
mass media, education and treatment of sexually
transmitted infections for female sex workers, and
treatment of sexually transmitted infections in the
general population cost < $Int150 per DALY averted.
Voluntary counselling and testing costs < $Int350 per
DALY averted in both regions, while prevention of
mother to child transmission costs < $Int50 per
DALY averted in Afr-E but around $Int850 per DALY
in Sear-D. School based education strategies and
various antiretroviral treatment strategies cost
between $Int500 and $Int5000 per DALY averted.
Conclusions Reducing HIV transmission could be
done most efficiently through mass media campaigns,
interventions for sex workers and treatment of
sexually transmitted infections where resources are
most scarce. However, prevention of mother to child
transmission, voluntary counselling and testing, and
school based education would yield further health
gains at higher budget levels and would be regarded
as cost effective or highly cost effective based on
standard international benchmarks. Antiretroviral
therapy is at least as cost effective in improving
population health as some of these interventions.
Introduction
The sixth millennium development goal, adopted by
the United Nations in 2000, aims to halt by 2015 and
begin to reverse the spread of HIV/AIDS. However,
most countries face uncertain prospects of attaining
this target. Shortage of resources is one important rea-
son for slow progress; the projected funding gap for
the year 2007 is estimated at around 50% of the need.1
In this study we focus on two related issues—whether
resources currently available are achieving as much as
they could and how best to use any new resources that
become available.
The millennium development goals were defined
when antiretroviral drugs were widely regarded as
being prohibitively expensive. The goal for HIV/AIDS
therefore focused on reducing transmission. Since
then, the annual cost of first line antiretrovirals has
fallen frommore than US$10 000 per patient to as low
as $140.2 While halting the spread of HIV infection
remains a critical—and unfulfilled—objective, there is
also an urgent need to assess the extent to which treat-
ment improves population health and is consistent
with the intent of the goals. With the recent price
reductions, re-evaluation of the cost effectiveness of
treatment is essential.
This paper assesses the effectiveness and costs of a
variety of interventions for preventing and treating
HIV/AIDS, individually and in combinations that
incorporate interactions between interventions in both
costs and health impacts. The analyses focus on two
particular regions with high HIV/AIDS burdens,
classified using the World Health Organization
epidemiological grouping—Afr-E, which includes
those countries in sub-Saharan Africa with very high
adult and high child mortality, and Sear-D, which
includes those countries in South East Asia with high
adult and high child mortality.
Methods
Another article in this series provides details on the
standardised methods used in all analyses in the series.3
In this section we provide a brief overview of methods
exclusive to this paper. (See bmj.com for complete
details on modelling intervention effects, estimating
costs, and sensitivity and uncertainty analyses.)
Strategies for HIV/AIDS control
We considered the range of available interventions for
preventing the spread of HIV infection in generalised
epidemics and various strategies for treating people
with HIV/AIDS. Our choice of interventions (see box)
was limited by available data4 and restricted to
strategies that are most relevant to the epidemics in
sub-Saharan Africa and South East Asia, where
transmission occurs mostly through heterosexual
contact.
Further details of the methods used appear in an appendix on
bmj.com
This is the abridged version of an article that was posted on
bmj.com on 10 November 2005: http://bmj.com/cgi/doi/
10.1136/bmj.38643.368692.68
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Model
We adapted an existing model of the transmission and
natural course of HIV/AIDS that was used previously
to assess the potential impact of preventive interven-
tions.5 The model includes underlying regional
demography, acquisition of HIV and other sexually
transmitted infections, and progression from HIV
infection to AIDS and death.
Results
Intervention effects
In both Afr-E and Sear-D regions the largest number
of disability adjusted life years (DALYs) are averted
through education and treatment of sexually transmit-
ted infections for sex workers, while the smallest gains
are from school based education. Tables 1and 2 show
the incremental cost effectiveness ratios for interven-
tions, listed in the order that they would be added with
increasing budgets if cost effectiveness were the only
consideration. The figure shows this expansion path
graphically, with the slope of the line joining any two
points indicating the incremental cost effectiveness
ratio for the more costly option (see related article by
Evans et al3 for further details). The size of intervention
benefits reported here should not be compared with
current epidemiological estimates since we compared
interventions against a “no intervention” scenario,
which subtracts current levels of condom use,
treatment of sexually transmitted infections, and
antiretroviral treatment.
The expansion paths for the two regions are
similar. Interventions focused on mass media and peer education and treatment of sexually transmitted infec-
tions for sex workers would be adopted first if cost
effectiveness were the only criterion for prioritising
interventions. In Afr-E health gains, measured in
DALYs, would be maximised by adding prevention of
mother to child HIV transmission and treatment of
sexually transmitted infections in the community next,
followed by voluntary counselling and testing, antiret-
roviral therapy, and school based education. All of
these interventions are highly cost effective based on
standard benchmarks.3 Using second line drugs in
antiretroviral regimens would be the last addition to
the package of interventions in Afr-E. In Sear-D
decision makers considering only the maximisation of
population health would add treatment of sexually
transmitted infections in the community, voluntary
counselling and testing, antiretroviral therapy (with
first line drugs), and prevention of mother to child
transmission—all highly cost effective3—before adding
school based education or second line antiretrovirals.
Many sources of uncertainty cannot be captured in
the usual statistical confidence intervals, including
uncertainty about the quantity of inputs required to
run a programme, the actual use of services by
patients, and unit costs. We tested the sensitivity of the
rankings to variation in the assumptions around key
parameters, and the ranking of interventions remained
stable (see appendix for details).
In Afr-E a reduction in programme costs relative to
patient costs would make treatment of sexually
transmitted infections at high coverage and school
based education more cost effective. In Sear-D an
increase in programme relative to patient costs would
make preventing mother to child transmission more
Interventions for HIV/AIDS considered in this analysis
Mass media—Includes television and radio episodes and inserts in key
newspapers, repeated every two years; development and administration
costs included; effectiveness scaled by proportion of population reporting
weekly exposure to radio, television, or newspapers
Voluntary counselling and testing—Performed in primary care clinics for
anyone requesting the services; includes training of health workers; based
on rapid test; number of tests over five year period assumed to be twice
average annual prevalence
Peer education for sex workers—Training of selected sex workers by social
workers to undertake peer education; provision of condoms
Peer education and treatment of sexually transmitted infections for sex workers—In
addition to training of sex workers for peer education, referrals made for
testing and possible treatment of sexually transmitted infections
School based education—Targeted at youths aged 10-18 years; sessions
provided during regular lessons to all students, to promote prevention of
HIV and other sexually transmitted infections; includes training of selected
teachers at each school
Treatment of sexually transmitted infections (general population)—Provided in
primary care facilities, available to anyone who requests it; includes visits,
drugs, counselling, advice on protection, and condom distribution if
requested; effectiveness scaled by access and likelihood of using the services
Prevention of mother to child transmission—Information provided to women
seeking antenatal care on benefits and risks of nevirapine for prophylaxis;
pre-test counselling offered; single dose provided to women who accept,
and single dose provided to child if delivered in a healthcare facility
Highly active antiretroviral therapy (HAART)—Standard HAART involves
monthly visits to healthcare providers, while intensive monitoring involves
weekly contact; either first line drugs only or first line drugs plus second
line drugs when required
See appendix on bmj.com for further details
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attractive relative to other interventions. Uncertainty
analyses also reveal stable outcomes across a range of
plausible behavioural and biological assumptions in
the 10 best fitting parameter sets (calibrated to match
baseline projections) (see bmj.com for details).
Discussion
This study re-examines HIV/AIDS intervention strate-
gies in a way that allows critical assessment of the cost
effectiveness of current strategies and plans for the
future use of extra resources that may become
available.We have evaluated interventions singly and in
combination, taking into account synergies in both
costs and effects when interventions are implemented
concurrently.
Because of the substantial uncertainties in many
of our assumptions, we suggest that our results be
viewed by broad bands of incremental cost effective-
ness ratios. For example, in sub-Saharan Africa mass
media and providing education and treatment of
sexually transmitted infections for sex workers are
virtually indistinguishable in terms of incremental
cost effectiveness, but we can be more confident
that school based education, at around $Int600
per DALY averted—even subject to a relatively wide
range of uncertainty—requires greater resources to
produce a given health benefit than peer education of
sex workers, at less than $Int5 per DALY; or that use
of second line antiretrovirals, at around $Int5000
per DALY averted, is substantially more costly
per healthy life-year gained than the initial introduc-
tion of first line antiretrovirals, at about $Int500 per
DALY.
Implications of results
Our results indicate that syndromic management of
sexually transmitted infections can substantially
reduce the health burden of HIV/AIDS in the
population. There has been extensive debate over the
role of treating sexually transmitted infections in the
prevention of HIV infection because of apparently
discrepant findings in three large, community based
trials.6–10 Our results are consistent with recent synthe-
ses of the findings from these trials,11 12 which
conclude that such treatment has substantial potential
Table 1 Annual costs in international dollars ($Int),* DALYs averted, and incremental cost effectiveness of non-dominated† intervention combinations to
control HIV/AIDS in Afr-E region
Intervention package Yearly costs
($Int, millions)
Yearly DALYs averted
(millions)‡
Incremental cost effectiveness
ratio ($Int/DALYs averted)No Details
D1 Mass media 16 4.5 3
D2 D1 + peer education and treatment of sexually transmitted infections for sex workers, 50% coverage 57 15.6 4
D3 D1 + peer education and treatment of sexually transmitted infections for sex workers, 80% coverage 79 21.3 4
D4 D1 + peer education and treatment of sexually transmitted infections for sex workers, 95% coverage 89 23.8 4
D5 D4 + prevention of mother to child transmission, antenatal care coverage level 249 27.3 46
D6 D5 + treatment of sexually transmitted infections, current coverage 290 27.9 68
D7 D5 + treatment of sexually transmitted infections, antenatal care coverage 357 28.7 80
D8 D7 + voluntary counselling and testing, 95% coverage 742 30.5 220
D9 D8 + treatment of sexually transmitted infections, expanded to 95% coverage 859 30.9 290
D10 D9 + antiretroviral therapy, no intensive monitoring, first line drugs only 2125 33.2 547
D11 D10 + school based education, 95% coverage 2202 33.3 631
D12 D11 + antiretroviral therapy, intensive monitoring, first line drugs only 2350 33.4 1144
D13 D11 + antiretroviral therapy, intensive monitoring, first and second line drugs 7483 34.4 5175
*International dollars are a hypothetical unit of currency that has the same purchasing power that the US$ has in the United States at a given point in time. Details of this approach are
discussed elsewhere.3
†Excludes combinations that were more costly but less effective than others (dominated interventions) and those with higher incremental cost effectiveness ratios than more effective options
(weakly dominated interventions).
‡Intervention benefits are not comparable with current epidemiological estimates because results in this analysis are computed in relation to a “no intervention” comparator, which subtracts
current levels of condom use, treatment of sexually transmitted infections, and antiretroviral treatment.
Table 2 Annual costs in international dollars ($Int),* DALYs averted, and incremental cost effectiveness of non-dominated† intervention combinations to
control HIV/AIDS in Sear-D region
Intervention package Yearly costs
($Int, millions)
Yearly DALYs averted
(millions)‡
Incremental cost effectiveness
ratio ($Int/DALYs averted)No Details
D1 Peer education and treatment of sexually transmitted infections for sex workers, 50% coverage 83 29.9 3
D2 Peer education and treatment of sexually transmitted infections for sex workers, 80% coverage 122 42.1 3
D3 Peer education and treatment of sexually transmitted infections for sex workers, 95% coverage 141 46.6 4
D4 D3 + mass media, 100% coverage 175 47.3 51
D5 D4 + treatment of sexually transmitted infections, 95% coverage 511 49.8 133
D6 D5 + voluntary counselling and testing, 95% coverage 693 50.4 317
D7 D6 + antiretroviral therapy, no intensive monitoring, first line drugs only 1149 51.0 760
D8 D7 + prevention of mother to child transmission, antenatal care coverage level 1416 51.3 850
D9 D8 + antiretroviral therapy, intensive monitoring, first line drugs only 1443 51.3 1295
D10 D9 + school based education, 95% coverage 1620 51.4 2192
D11 D10 + antiretroviral therapy, intensive monitoring, first and second line drugs 2481 51.6 4406
*International dollars are a hypothetical unit of currency that has the same purchasing power that the US$ has in the United States at a given point in time. Details of this approach are
discussed elsewhere.3
†Excludes combinations that were more costly but less effective than others (dominated interventions) and those with higher incremental cost effectiveness ratios than more effective options
(weakly dominated interventions).
‡Intervention benefits are not comparable with current epidemiological estimates because results in this analysis are computed in relation to a “no intervention” comparator, which subtracts
current levels of condom use, treatment of sexually transmitted infections, and antiretroviral treatment.
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to reduce HIV transmission, particularly in HIV
epidemics at less advanced stages, as in both of the
regions examined here (compared with the epidemic
in Uganda). Our conclusion that treating sexually
transmitted infections would be among the most cost
effective interventions against HIV transmission
should, however, be revisited as new information
emerges.
Another important finding is that antiretroviral
therapy would be included in a package of interven-
tions for HIV/AIDS in both regions on the basis of
cost effectiveness. A strict literal interpretation of the
stated targets in the millennium development goals
would limit the focus to interventions that reduce
transmission, and evidence on the impact of treatment
on transmission remains limited. However, treatment
offers relatively good value for money in both regions
in terms of broad measures of population health
outcomes. Cost effectiveness ratios for first line
HAART are lower than those for school based educa-
tion, and some variant of HAART falls well below the
threshold for very cost effective interventions in both
regions. Although we found the addition of second line
antiretrovirals to be relatively costly per added year of
healthy life, their prices could well fall, as did the costs
of first line treatment, which would lower these cost
effectiveness ratios accordingly.
In addition, the direct impacts of antiretroviral
therapy reported here might understate the overall
social benefits of treatment. For example, the availabil-
ity of treatment may encourage people to present vol-
untarily for counselling and testing, which is critical to
overcoming denial, stigma, and discrimination—
among the main barriers to effective prevention. It
would also allow key workers such as those in the
medical and education sectors to report more
regularly for work, thereby relieving staff shortages in
those sectors in many countries. These issues reinforce
the finding that antiretrovirals should be offered in
combination with preventive strategies.
Limitations of study
Several limitations in this study deserve mention. Some
interventions that were not included in this analysis
may be effective strategies. In addition, the interven-
tions that we did include have been formulated in a
small number of ways among the many possibilities.
For example, we considered a basic variant of prevent-
ing mother to child transmission that falls short of the
most recently published official recommendations.13
Although a regional analysis is intended to provide
broad guidance to decision makers, many factors can
cause variability in both costs and effects of
interventions across settings. Although they are
unlikely to affect our overall conclusions, continuing
efforts are required to expand the scope of strategies
that are analysed and consider additional alternatives
for feasible implementation.
Many important uncertainties remain about the
trajectory of HIV/AIDS epidemics and the potential
effectiveness of interventions when expanded to full
scale. Developing a better understanding of sexual
behaviours in different settings will be critical, as will
strengthening the empirical link between behavioural
and epidemiological models. In considering the likely
impact of interventions, we extrapolated most assump-
tions from a limited number of relatively small scale
studies, so precise and reliable estimates of the
effectiveness of large scale prevention programmes are
still needed.
Conclusions
We emphasise that decisions are never made only on
cost effectiveness criteria. Many other factors influence
priority setting. For HIV/AIDS in particular, argu-
ments have been made in support of general or
specific intervention strategies based on ethical criteria
and human rights, so policy makers should interpret
our results in the context of these other important
considerations.
A previous analysis indicated that the millennium
development goal for HIV/AIDS could be achieved by
application of a comprehensive response to preven-
tion and treatment.14 Our analysis suggests that the
financial constraints to implementing such a compre-
hensive approach to combating HIV/AIDS should not
be regarded as the principal obstacle. A critical policy
question that remains, however, is how to ensure that
the massive undertaking required to respond effec-
tively to the HIV pandemic can be sustained. Our find-
ings that a combination of prevention and treatment
can be highly cost effective brings into sharper focus
the importance of overcoming other constraints such
as managerial needs, political commitment, infrastruc-
ture, and human resource requirements.
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What is already known on this topic
Previous studies of intervention priorities for
HIV/AIDS in resource poor settings have either
focused on comprehensive intervention packages
or assembled cost effectiveness outcomes from
independent studies of individual interventions
Recent reductions in costs of antiretroviral drugs
make re-evaluation of the cost effectiveness of
treatment essential
What this study adds
A comprehensive and standardised analysis of
available interventions singly and in different
combinations shows that “best buys” in HIV
prevention include mass media campaigns,
interventions focused on female sex workers, and
treatment of other sexually transmitted infections
Cost effectiveness criteria would support the
inclusion of antiretroviral therapy in a package of
high value interventions, and treatment is
expected to produce other benefits not captured
in a cost effectiveness framework
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Parental concerns about their child’s emotions and
behaviour and referral to specialist services: general
population survey
Tamsin Ford, Kapil Sayal, Howard Meltzer, Robert Goodman
Childhood psychiatric disorders are common and are
associated with heavy use of health services.1 Up to a
third of children and adolescents attending primary
care and paediatric outpatient departments have clini-
cally significant psychopathology.2 3 Only a minority of
these children reach specialist mental health services,
partly because the presenting complaint is rarely
psychological, so their disorders may not be recog-
nised.2 4 Child mental health services may reject
inappropriate referrals leading to frustration among
referrers and families.
Although medical professionals often depend on
parental concerns to identify affected children, we do
not know how predictive they are. We used empirical
data from the 1999 British child and adolescent men-
tal health survey to examine how predictive parental
perceptions of psychological difficulties were of
psychiatric disorder and to provide simple strategies
to aid clinicians in identifying children requiring
referral.1
Participants, methods, and results
We used the child benefit register to select a nationally
representative sample of 10 438 children aged 5-15
years from Great Britain. The Development and Well
Being Assessment combined information from par-
ents, teachers, and young people aged 11 and older to
diagnose psychiatric disorders according to the
Diagnostic and Statistical Manual of Mental Disorders,
fourth edition.5 Parents completed the Strengths and
Difficulties Questionnaire, which generates total
difficulties and impact scores.6 The latter indicates the
level of distress and related impairment in family life,
peer relationships, academic functioning, and leisure
activities.
Parents were also asked whether their child had
“hyperactivity,” “behavioural problems,” and “emo-
tional problems” and whether teachers had com-
plained about the child’s concentration, activity level, or
impulsiveness. We cross tabulated parents responses to
these questions with the presence of psychiatric disor-
der to elicit ways in which clinicians might assess which
children require referral.
The negative predictive power and specificity of
parental opinions were high, suggesting that clinicians
can mostly be reassured by a lack of parental concern
(table). About half of the children that parents were
worried about had a psychiatric disorder; almost three
quarters of parents reported problems in more than
one area. Many of the children identified as having dif-
ficulties by parents will have significant problems even
if they fall below the threshold for a psychiatric
diagnosis. The Strengths and Difficulties Question-
naire total symptoms and impact scores were much
higher in the “parent concerned but no diagnosis”
group (n = 396) than the “no parental concern” group
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